FiercePharma

Sanofi-aventis: Adding Lantus(R) to Oral Antidiabetic Drug Therapy Further Reduced Blood Sugar in Patients With Type 2 Diabetes

Sanofi-aventis: Adding Lantus(R) to Oral Antidiabetic Drug Therapy Further Reduced Blood Sugar in Patients With Type 2 Diabetes - Findings Presented at European Association for the Study of Diabetes ...
EurekAlert!

Ultra rapid lispro improves postprandial glucose control versus lispro in combination with insulin glargine/degludec in adults with type 2 diabetes: a prospective, randomized ...

This study is led by Prof. Weiping Jia (Department of Endocrinology and Metabolism, Shanghai Jiao Tong University School of Medicine Affiliated Sixth People’s Hospital). Despite the range of available ...
FierceBiotech

Adocia Initiates Two Clinical Studies on Its Combination of Long-Acting Insulin Glargine and Fast-Acting Insulin Lispro, BioChaperone® Combo

Adocia (Paris:ADOC)(Euronext Paris: FR0011184241 – ADOC) announces today the initiation of two Phase Ib clinical trials evaluating its innovative formulation combining insulin glargine (Lantus, Sanofi ...
FiercePharma

Adocia announces preliminary positive clinical results for its combination of long-acting insulin Glargine and fast-acting insulin analog Lispro, Biochaperone(R) Combo

Adocia announces preliminary positive clinical results for its combination of long-acting insulin Glargine and fast-acting insulin analog Lispro, Biochaperone(R) Combo Adocia's BioChaperone Combo is ...
FierceBiotech

Adocia confirms positive clinical results for its BioChaperone(R) Combo, a combination of long-acting insulin glargine and fast-acting insulin lispro

Adocia confirms positive clinical results for its BioChaperone(R) Combo, a combination of long-acting insulin glargine and fast-acting insulin lispro BioChaperone Combo is the first combination based ...